Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Wed, 26th Oct 2022 07:00
RNS Number : 1016E
DeepMatter Group PLC
26 October 2022
26 October 2022
DeepMatter Group Plc
Trading update
DeepMatter Group Plc (AIM: DMTR, "Deepmatter", the "Group"), the digital chemistry data and software company, announces that after the nine months of the financial year and having now signed a material agreement with Merck (see separate statement), the Group expects revenue for the current financial year to be no less than £1.5m, an increase of over 50% year on year (2021: £1.0m).
DeepMatter has secured three strategically important multi-year collaborations during the current financial year and as anticipated continues to see a strengthening of its sales pipeline following a strong first half. The Merck collaboration has the potential to become one of the Group's largest to date.
These collaborations bring future revenue visibility and opportunities to grow the revenue opportunity from existing customers as well as new customers. They include technology access fees, collaboration fees and royalties.
As stated in the Group's H1 results, DeepMatter is investing in product enhancements, strengthening its team, pursuing machine learning (ML) and artificial intelligence (AI) based R&D activities that create new intellectual property (IP). It also continues to assert its IP rights which have the potential to contribute to long term value creation. The Directors remain in regular contact with the Group's major shareholders who are supportive. Deepmatter held cash balances of £0.7m at 30 September 2022, with costs remaining in line with those reported at the time of Group's H1 results.
Additionally, ChemIntelligence, which DeepMatter acquired in June 2022, has been selected by Bayer CropScience, the world's second largest agrochemical company, to provide its capabilities in Bayer's LifeHub Lyon in La Dargoire Research Centre (CRLD).
The inclusion of ChemIntelligence in the LifeHub should accelerate the safe design and more effective development of chemical crop protection products using its artificial intelligence expertise and intellectual property.
Can’t see a negative
Mark Warne, CEO of DeepMatter, commented:
"After a solid H1, we are now on course to increase our year on year revenues by some 50% and importantly are seeing increasing customer interest and the potential for recurring royalty revenues. These revenues which are recognised over the life of contracts, providing us with growing visibility.
"With our strengthening relations with Merck and other international blue chip organisations plus our investment programme, we are leading the digitalisation of chemistry space and driving the market shift. Our vision is to provide the digital data that enables all molecules to be made efficiently and safely as well as sustainably."